ClinicalTrials.gg
CompletedNCT07395908Updated Nov 18, 2026

The Effect of Interventional Procedures on Serum CGRP and PACAP-38 Levels in Chronic Migraine

An interventional study of Greater occipital nerve Pulse radiofrequency and Greater occipital nerve block in Chronic Migraine Headache, Radiofrequency Ablation and Greater Occipital Nerve Block, sponsored by Aydin Adnan Menderes University. Completed at 1 site in Turkey (Türkiye). Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Aydin Adnan Menderes University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now CompletedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Migraine Disorders with a site in Turkey — 20 open to participants now, 25 under way, 3 of them phase 3. Migraine Disorders · Turkey.

Enrollment
24th of 69
100 · median 73
Started
2026
with 8 others
No phase
56 of 92
13 open now
Registered
84th of 92
by date

Among the 92 studies in Migraine Disorders with a site in Turkey, this one is the 24th largest by enrollment of the 69 interventional ones that give a count, is one of 9 that started in 2026, is one of 56 with no phase, and was the 84th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

20 of the 92 studies in Migraine Disorders with a site in Turkey are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Migraine Disorders with a site in Turkey, or all of them as a file.
02

Study summary

The study included 100 patients diagnosed with chronic migraine (CM) who received a diagnosis from the headache clinics of the Neurology Department of Adnan Menderes University Hospitals between May 2025 and May 2026. Inclusion criteria were patients over 18 years of age with chronic migraine. Written informed consent was obtained from all participants; patients with severe systemic diseases, occiput infections or injuries, and allergies to any of the substances used in the injection were excluded. All patients were clinically evaluated (detailed history including personal data, medical history, and migraine treatments used). All patients underwent ultrasound-guided bilateral GON blockade using a portable ultrasound system with a 7-13 MHz multifrequency transducer (ACUSON Juniper Ultrasound System, Siemens, Germany). Blood samples were collected before and one month after the procedure. Samples were collected between 9 and 11 am to avoid the effect of circadian rhythms on CGRP levels. Patients will need to discontinue any anti-inflammatory or analgesic medication within the last 48 hours. A blood sample will be taken from the non-dominant forearm to measure interictal serum CGRP-PACAP38 levels using commercial ELISA kits (Novus Biologicals Inc., USA) according to the manufacturer's instructions. Absorption levels will be measured with a spectrophotometer at a wavelength of 450 nm ± 2 nm. The detection limit for CGRP is 9.3 pg/mL.

Read the detailed description

Preoperative Visit:

During the preoperative visit, patients' additional illnesses, demographic data, and medication use will be recorded. The patients' NRS (Numerating Rating Scale) score will be recorded. Antebrachial venous blood samples will be taken along with routine samples requested after the outpatient examination.

Intraoperative Nerve Block Procedure:

All procedures were planned to be performed under sterile conditions with ultrasound guidance while the patient was in the prone position.

GON Block: The ultrasound probe was placed in a transverse plane 2-3 cm lateral to the Protuberantio Ocipitalis Externa. After visualizing the occipital artery, it was targeted medial to the GON artery. After local anesthesia with 1% lidocaine (skin-subcutaneous), a 21 Gauge 5 cm long needle tip was guided from lateral to medial using an in-plane approach to precisely place it in the center of the nerve for the block (Figure 2). After negative acission, the block was performed with 3 ml of 2% Prilocaine. Supraorbital/supratrochlear nerve block: The ultrasound probe is placed along the supraorbital notch, through the medial third of the supraorbital border. The supraorbital nerve (SON) and the supratrochlear nerve (STN) are located just above its medial border. 2 cc of 2% prilocaine is injected into the target using a 5 cm, 21 gauge needle and inplane technique.

Intraoperative Pulse Radiofrequency procedure:

For radiofrequency, a 5 cm long RF cannula with a 5 mm active tip is placed in the target under ultrasound guidance, and the needle tip is guided from laterally to medially using an inplane approach to precisely center the nerve. To induce a congruent paresthesia response in the occipital nerve distribution, 50 Hz 1v sensory and 2 Hz 2v motor electrical stimulation was performed with an SMK (Select RF StraightCannula, 100mm, 22G, 10mm active tip SMK-S1010-22) RF electrode. Pulsed radiofrequency (Neurotherm NT1100 / 13001-12) will be applied at 42°C for 240 seconds.

Patients will be observed after the procedure. Patients who do not experience postoperative complications and are mobile will be discharged at 2 hours. Patients may withdraw from the study at any time.

Patients meeting the eligibility criteria will be informed in detail about the procedure. Written and verbal consent will be obtained from the patients.

Post-operative visits:

Venous blood sampling will be performed one month after the procedure, along with routine samples requested after the outpatient examination.

Samples were collected between 9 and 11 a.m. to avoid the influence of circadian rhythms on CGRP levels. Subjects were required to discontinue any anti-inflammatory or analgesic medication in the previous 48 hours. Blood samples were taken from the non-dominant forearm to measure interictal serum CGRP levels using commercial ELISA kits (Novus Biologicals Inc., USA) following the manufacturer's instructions. Absorption levels were measured with a spectrophotometer at a wavelength of 450 nm to 2 nm. The detection limit of the test was considered to be 9.3 pg/ml for CGRP.

For PACAP 38, blood samples were collected into ice-cold glass tubes containing the anticoagulant ethylenediaminetetraacetic acid (EDTA, 12 mg) and the protease inhibitor aprotinin (Trasylol, 1200 IU) and kept at 4°C until centrifuged (2000 rpm for 10 minutes at 4°C). Plasma samples will be stored at -80°C until measured by PACAP-38.

Pain intensity will be assessed using the NRS (Numerical Rating Scale) at 1, 3, and 6 months post-procedure.

The NRS is a pain intensity assessment system based on a system where the individual describes their pain on a scale of 0 (none) to 10 (unbearable pain).

03

Conditions studied

  • Chronic Migraine Headache
  • Radiofrequency Ablation
  • Greater Occipital Nerve Block
  • Calcitonin Gene-related Peptide
  • Pacap-38

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Being over 18 years of age
  2. Having given written consent
  3. Patients diagnosed with chronic migraine

Exclusion criteria

Exclusion Criteria:

  1. Major psychiatric illness
  2. Patients using anticoagulant agents

4. Patients with infection in the procedure area 5. Patients allergic to local anesthetics 6. Pregnant women 7. Patients with cardiac pacemakers

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    patients to whom applied radiofrequency

    For radiofrequency, a 5 cm long RF cannula with a 5 mm active tip is placed in the target under ultrasound guidance, and the needle tip is guided from laterally to medially using an inplane approach to precisely center the nerve. To induce a congruent paresthesia response in the occipital nerve distribution, 50 Hz 1v sensory and 2 Hz 2v motor electrical stimulation was performed with an SMK (Select RF StraightCannula, 100mm, 22G, 10mm active tip SMK-S1010-22) RF electrode. Pulsed radiofrequency (Neurotherm NT1100 / 13001-12) will be applied at 42°C for 240 second

    Procedure: Greater occipital nerve Pulse radiofrequency

  • Active comparator
    patients to whom applied greater occipital nerve block

    The ultrasound probe was placed in a transverse plane 2-3 cm lateral to the Protuberantio Ocipitalis Externa. After visualizing the occipital artery, it was targeted medial to the GON artery. After local anesthesia with 1% lidocaine (skin-subcutaneous), a 21 Gauge 5 cm long needle tip was guided from lateral to medial using an in-plane approach to precisely place it in the center of the nerve for the block (Figure 2). After negative acission, the block was performed with 3 ml of 2% Prilocaine. Supraorbital/supratrochlear nerve block: The ultrasound probe is placed along the supraorbital notch, through the medial third of the supraorbital border. The supraorbital nerve (SON) and the supratrochlear nerve (STN) are located just above its medial border. 2 cc of 2% prilocaine is injected into the target using a 5 cm, 21 gauge needle and inplane technique.

    Procedure: Greater occipital nerve block

Interventions

  • ProcedureGreater occipital nerve Pulse radiofrequency

    For radiofrequency, a 5 cm long RF cannula with a 5 mm active tip is placed in the target under ultrasound guidance, and the needle tip is guided from laterally to medially using an inplane approach to precisely center the nerve. To induce a congruent paresthesia response in the occipital nerve distribution, 50 Hz 1v sensory and 2 Hz 2v motor electrical stimulation was performed with an SMK (Select RF StraightCannula, 100mm, 22G, 10mm active tip SMK-S1010-22) RF electrode. Pulsed radiofrequency (Neurotherm NT1100 / 13001-12) will be applied at 42°C for 240 seconds.

  • ProcedureGreater occipital nerve block

    The ultrasound probe was placed in a transverse plane 2-3 cm lateral to the Protuberantio Ocipitalis Externa. After visualizing the occipital artery, it was targeted medial to the GON artery. After local anesthesia with 1% lidocaine (skin-subcutaneous), a 21 Gauge 5 cm long needle tip was guided from lateral to medial using an in-plane approach to precisely place it in the center of the nerve for the block (Figure 2). After negative acission, the block was performed with 3 ml of 2% Prilocaine. Supraorbital/supratrochlear nerve block: The ultrasound probe is placed along the supraorbital notch, through the medial third of the supraorbital border. The supraorbital nerve (SON) and the supratrochlear nerve (STN) are located just above its medial border. 2 cc of 2% prilocaine is injected into the target using a 5 cm, 21 gauge needle and inplane technique.

06

What researchers measure

Primary outcomes

  1. The aim of this study is to investigate the effectiveness of nerve block and radiofrequency treatments in patients with chronic migraine using biochemical migraine biomarkers

    It was planned to measure venous blood CGRP and PACAP38 levels in patients with chronic migraine before the interventional procedure and one month after the procedure.

    Time frame: 1 month

Secondary outcomes

  1. The secondary outcome of this study is to compare the effectiveness of nerve block and radiofrequency treatments on chronic pain in patients with chronic migraine.

    To evaluate the effectiveness of nerve block and radiofrequency treatments in patients with chronic migraine, a numerical rating scale (NRS) was planned to be applied before the procedure, and at 1, 3, and 6 months after the procedure. An NRS reduction of 50% or more was considered significant.

    Time frame: 6 months

07

Study locations

1 site
  • Adnan Menderes University Efeler / Aydın
    Aydin, 09100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Nov 2026, 8 months.

Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 8 months is below that.

Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start May 2025 → Feb 2026, primary completion May 2026 → Nov 2026 and completion Jun 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 9, 2026
StartActual
Feb 3, 2026was May 2025
Primary completionActual
Nov 2, 2026was May 2026
CompletionActual
Nov 2, 2026was Jun 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 18, 2026
Start date
May 29, 2025→Feb 3, 2026
Nov 18, 2026
Primary completion
May 2026→Nov 2, 2026 (actual)
Nov 18, 2026
Study completion
Jun 2026→Nov 2, 2026 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Active, not recruiting→Completed
    Start date May 29, 2025→Feb 3, 2026
    Primary completion May 2026→Nov 2, 2026 (now actual)
    Study completion Jun 2026→Nov 2, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07395908
Responsible party
Esra Ertilav (Assoc. Prof., Aydin Adnan Menderes University) — Principal investigator
First posted
Feb 9, 2026
Start date
Feb 3, 2026
Primary completion
Nov 2, 2026
Completion
Nov 2, 2026
Last update
Nov 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion